WHAT KEEPS OUR BONES STRONG?

Similar documents
Clinician s Guide to Prevention and Treatment of Osteoporosis

Building Bone Density-Research Issues

Osteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis

Overview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence

Nutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio

Osteoporosis. Overview

Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC

Skeletal Manifestations

Chapter 39: Exercise prescription in those with osteoporosis

BONE HEALTH Dr. Tia Lillie. Exercise, Physical Activity and Osteoporosis

To understand bone growth and development across the lifespan. To develop a better understanding of osteoporosis.

The Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD

Osteoporosis: Who, What, When, Why, and How

Calcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD

AACE/ACE Osteoporosis Treatment Decision Tool

Osteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.

CASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS

Osteoporosis - At a Glance

Osteoporosis in Men Wendy Rosenthal PharmD. This program has been brought to you by PharmCon

Bone health. Kirstie Stenhouse, NHS Forth #ACFALLS2018 #SPSP10

1

Guideline for the investigation and management of osteoporosis. for hospitals and General Practice

Additional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015. Dr.

Horizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre

Osteoporosis Update. Greg Summers Consultant Rheumatologist

nogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK

Osteoporosis after Spinal Cord Injury

Updates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1

Management of postmenopausal osteoporosis

Osteoporosis: An Overview. Carolyn J. Crandall, MD, MS

Osteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK

Kristen M. Nebel, DO PENN/ LGHP Geriatrics. Temple Family Medicine Review

Learning Objectives. Controversies in Osteoporosis Prevention and Management. Etiology. Presenter Disclosure Information. Epidemiology.

Challenging the Current Osteoporosis Guidelines. Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA

TREATMENT OF OSTEOPOROSIS

Fragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey

Objectives: What is Osteoporosis 10/8/2015. Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING

Using the FRAX Tool. Osteoporosis Definition

Assessment and Treatment of Osteoporosis Professor T.Masud

Interpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm

Osteoporosis. Treatment of a Silently Developing Disease

Objectives. Discuss bone health and the consequences of osteoporosis on patients medical and disability status.

Vasu Pai FRACS, Nat Board, MCh, M.S

Horizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329

Helpful information about bone health & osteoporosis Patient Resource

Diagnosis and Treatment of Osteoporosis. Department of Endocrinology and Metabolism Ajou University School of Medicine.

New 2010 Osteoporosis Guidelines: What you and your health provider need to know QUESTIONS&ANSWERS

Ca, Mg metabolism, bone diseases. Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary

Prevention and Treatment of OSTEOPOROSIS 骨質疏鬆的預防與治療

Aromatase Inhibitors & Osteoporosis

Forteo (teriparatide) Prior Authorization Program Summary

The Skeletal Response to Aging: There s No Bones About It!

Orthopantomogram as an effective tool for the diagnosis of osteoporosis-a study

Summary. Background. Diagnosis

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF NEW MEDICINAL PRODUCTS IN THE TREATMENT OF PRIMARY OSTEOPOROSIS

Product: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1

OSTEOPOROSIS: PREVENTION AND MANAGEMENT

Bone Disease after Kidney Transplantation

ORIGINAL ARTICLE SERUM OSTEOCALCIN, SHALL WE CONSIDER IT AS A BIOCHEMICAL MARKER FOR OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

DOWNLOAD OR READ : OSTEOPOROSIS IN MEN SECOND EDITION PDF EBOOK EPUB MOBI

DEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN

[If no, skip to question 10.] Y N. 2. Does the member have a diagnosis of Paget s disease of bone? Y N. [If no, skip to question 4.

3. Has bone specific alkaline phosphatase level increased OR does the member have symptoms related to active Paget s?

Submission to the National Institute for Clinical Excellence on

Name of Policy: Boniva (Ibandronate Sodium) Infusion

This includes bone loss, endometrial cancer, and vasomotor symptoms.

9/26/2016. The Impact of Dietary Protein on the Musculoskeletal System. Research in dietary protein, musculoskeletal health and calcium economy

BMD: A Continuum of Risk WHO Bone Density Criteria

Osteoporosis. Osteoporosis ADD PICTURE

Download slides:

OSTEOPOROSIS IN INDONESIA

Bone Mineral Density and Its Associated Factors in Naresuan University Staff

Dietary Protein and Bone Health Emphasis: Animal Protein

BAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008

Osteoporosis in Men. Until recently, the diagnosis of osteoporosis. A New Type of Patient. Al s case. How is the diagnosis made?

BONE HEALTH BASICS. Promoting Healthy Bones: Sorting Out the Science. Learning Objectives. Guest Speaker

This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against

Elecsys bone marker panel. Optimal patient management starts in the laboratory

Silent Killer: Osteoporosis

Bone density scanning and osteoporosis

Correlation between Thyroid Function and Bone Mineral Density in Elderly People

Osteoporosis: A Tale of 3 Task Forces!

International Journal of Scientific & Engineering Research Volume 8, Issue 7, July-2017 ISSN ,393

Osteoporosis challenges

Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study

Page 1. New Developments in Osteoporosis. What s New in Osteoporosis

Osteoporosis/Fracture Prevention

S^t _j4 A-N.1^.^ A _ WE 2

ESPEN Congress Cannes Education and Clinical Practice Programme

Healthy Bones: Osteoporosis Management. Laurel Short, MSN, FNP-C

Advanced medicine conference. Monday 20 Tuesday 21 June 2016

LOVE YOUR BONES Protect your future

All about Osteoporosis symptoms, diagnosis, treatment

An audit of osteoporotic patients in an Australian general practice

Coordinator of Post Professional Programs Texas Woman's University 1

Page 1

John J. Wolf, DO Family Medicine

The Better Health News2

BONE MINERAL DENSITY OF BANGLADESHI PEOPLE

Page: 1 of 12. Bone Turnover Markers for Diagnosis and Management of Osteoporosis and Diseases Associated With High Bone Turnover

Transcription:

WHAT KEEPS OUR BONES STRONG? The role of diet and lifestyle in osteoporosis prevention Thomas Walczyk PhD, Associate Professor Food Science and Technology Programme Department of Chemistry, Faculty of Science Department of Biochemistry, Yong Loo Lin School of Medicine

!!! BONE IS NO DEAD MATTER!!!

BONE REMODELLING BONE-ACCRETION Osteoblasts Ca Osteoclasts BONE RESORPTION

BONE DIET - LIFESTYLE BONE-ACCRETION Genotype Ca Vitamin D Phytoestrogenes Body Weight Physical Activity Alcohol Coffee Salt Intake Protein-Intake Acid/Base Balance Smoking BONE RESORPTION

BONE MASS AND AGE BONE MASS PEAK BONE MASS males puberty menopause females 10 20 30 0 50 60 70 80 AGE (YEARS)

BONE MASS AND AGE Lis Roskilde Lis Roskilde Vertebra young female Vertebra old female

OSTEOPOROSIS = POROUS BONE A disease characterized by low bone mass and micro-architectural deterioration of bone tissue leading to enhanced bone fragility and a consequent increase in fracture risk. World Health Organization (WHO) 199

HIDDEN VERTEBRAE FRACTURES 5 years 75 years http://www.osteoporosezentrum.de/osteoporose/folgen.html

DANGER ZONES Solvay Pharma Vertebrae 1 in 6 women 1 in 20 men Wrist 1 in 6 women 1 in 0 men Femoral Neck 1 in 6 women 1 in 17 men Fracture Lifetime risk (western populations) 1 in 3 women and 1 in 5 man over 50 years International Osteoporosis Foundation / Kanis et al. 2000 / Melton 1992

PROJECTIONS - FOCAL POINT ASIA International Osteoporosis Foundation

CONSEQUENCES OF OSTEOPOROSIS Height loss, chronic pain affects self esteem, depression sleepless nights only 30% of osteoporotic patients fully regain their pre fracture level of independence Constipation, abdominal pain lumbar fractures may alter abdominal anatomy Limited mobility!!! REFERS BOTH TO MALES AND FEMALES!!!

SINGAPORE - FACTS AND FIGURES High prevalence among Singaporeans ca. 100,000 women suffer from osteoporosis ca. 800 to 900 osteoporotic hip fractures every year Sharp increase in hip fractures over past 3 decades in men and women (>50 years) 5 times in women from 75 cases to 02 cases per 100,000 populations 1.5 times in men from 103 cases to 152 cases per 100,000 populations High mortality and morbidity rate 1 in Singaporeans suffering an osteoporotic hip fracture die within one year after injury 1 in 3 became wheelchair bound or bedridden Source: International Osteoporosis Foundation (Country Factsheets 2007)

OSTEOPOROSIS PREVENTION BETTER CHOICE THAN THERAPY

ASSESSMENT OF CHANGES IN BONE METABOLISM Bone Mineral Density double emission X-ray absorptiometry (DEXA) computer-tomography (CT, q-ct, pq-ct, µ-ct) ultrasonic Techniques DXA measurement

ASSESSMENT OF CHANGES IN BONE METABOLISM Bone Mineral Density double emission X-ray absorptiometry (DEXA) computer-tomography (CT, q-ct, pq-ct, µ-ct) ultrasonic Techniques Biochemical Markers of Bone Metabolism degradation products of organic bone matrix in urine pyridinoline, desoxy-pyridinoline, telopeptides, sialoprotein compounds involved in bone accretion process osteocalcin, procollagen-polypeptide, alkaline phosphatase

LIMITATIONS OF AVAILABLE TECHNIQUES LIMITED SENSITIVITY = long monitoring periods STRONG INTRA-INDIVIDUAL VARIATIONS = large subject numbers

NUTRI TRACE LAB @ SCIENCE (S13) Exploration of mineral and trace element metabolism in humans by stable isotope tracer techniques for development and evaluation of strategies to improve public health through diet and lifestyle operational since 08/2008

NUTRI TRACE LAB @ SCIENCE (S13) CONTROLLED INTERVENTION STUDIES animal + men ASSESSMENT OF NUTRIENT INTAKE METABOLIC STUDIES USING ISOTOPE TECHNIQUES NUTRITIONAL STATUS

NUTRI TRACE LAB @ SCIENCE (S13) CONTROLLED INTERVENTION IRON STUDIES animal + men ASSESSMENT OF NUTRIENT INTAKE CALCIUM METABOLIC STUDIES USING ISOTOPE TECHNIQUES NUTRITIONAL STATUS

ISOTOPIC LABELING OF BONE CALCIUM SINGLE ADMINISTRATION OF CALCIUMISOTOPE

ISOTOPIC LABELING OF BONE CALCIUM SINGLE ADMINSITRATION OF CALCIUMISOTOPE INCORPORATION OF CALCIUM ISOTOPE INTO BONE MATRIX

ISOTOPIC LABELING OF BONE CALCIUM SINGLE ADMINSITRATION OF CALCIUMISOTOPE INCORPORATION OF CALCIUM ISOTOPE INTO BONE MATRIX URINARY TRACER SIGNAL = MEASURE OF BONE CALCIUM BALANCE

ISOTOPIC LABELING OF BONE CALCIUM CALCIUMISOTOPE TRACER SIGNAL IN URINE LABELING PHASE TIME

ISOTOPIC LABELING OF BONE CALCIUM TRACER SIGNAL IN URINE POSI TI VE EFFECT I NTERVENTI ON

ISOTOPIC LABELING OF BONE CALCIUM TRACER SIGNAL IN URINE NEGATI VE EFFECT I NTERVENTI ON

ISOTOPIC LABELING OF BONE CALCIUM TRACER SIGNAL IN URINE NEGATI VE EFFECT I NTERVENTI ON

WHAT ARE CALCIUM-ISOTOPES? increasing neutron number = increasing mass CALCIUM3 8 3 9 0 1 2 3 5 6 7 8 9 CALCIUM ISOTOPES = calcium atoms of different mass

STABLE VERSUS RADIOACTIVE ISOTOPES mass number abundance CALCIUM3 8 3 9 0 96.9% 1 2 0.65% STABLE ISOTOPES 3 0.1% 2.08% 5 6 0.00% 7 8 0.19% 9 Natural calcium = stable isotope mix Isotopic abundances highly constant Highly enriched stable isotopes can be used as tracers No health hazards Outrageous costs

STABLE VERSUS RADIOACTIVE ISOTOPES CALCI UM 3 8 38 0.s 3 9 39 0.9s 0 0 96.9% 1 1 1x10 5 a 2 2 0.65% 3 3 0.1% 2.08% mass number half-life 5 5 163d RADIOACTIVE ISOTOPES 6 6 0.00% 7 7.5d 8 8 0.19% 9 9 8.7m!!! HEALTH HAZARDS!!!

STABLE VERSUS RADIOACTIVE ISOTOPES effective dose < 1/1000 of standard chest x-ray CALCI UM 3 8 38 0.s 3 9 39 0.9s 0 0 96.9% 1 1 1x10 5 a 2 3 5 5 163d SEMI-STABLE RADIOACTIVE ISOTOPE 39 ISOTOPES5 38 0.s 2 0.65% 3 0.1% 2.08% 6 6 0.00% 7 7.5d 7 0.9s 1 very long 163d half-life.5d 1x10 5 a 8 8 0.19% 9 9 8.7m 9 8.7m = very slow decay (virtually stable) = very low radio-emission highly sensitive detection = low dosage

THE ANALYTICAL CHALLENGE Accelerator Mass Spectrometer ETH Zurich

THE ANALYTICAL CHALLENGE 1 Ca/nat. Ca in enriched samples: 10 - to 10-11 Accelerator Mass Spectrometer ETH Zurich

THE ANALYTICAL CHALLENGE SWITZERLAND ETH Zurich, Laboratory of Human Nutrition SWITZERLAND ETH Zurich, Institute of Particle Physics SWITZERLAND Paul Scherrer Institute, Villingen SWITZERLAND University Hospital Zurich, Clinical Pharmacology GERMANY University of Mainz, Institute of Physics ENGLAND Scottish Universities Environmental Research Centre East Killbride IRELAND University of Cork, Food and Nutritional Sciences EU EU Joint Research Center, Institute of Reference Materials and Measurements DENMARK The Danish Food and Veterinary Administration Institute of Food Research and Nutrition USA Lawrence Livermore National Laboratory USA Argonne National Laboratory Accelerator Mass Spectrometer ETH Zurich

EFFECT OF BISPHOSPHONATE THERAPY ON Ca- 1 SIGNAL BISPHOSPHONATES = POTENT INHIBITORS OF BONE RESORPTION LABELING PHASE single tracer dose (100 nci) 3 month bisphosphonate treatment 6 post-menopausal women with diagnosed osteopenia intervention

EFFECT OF BISPHOSPHONATE THERAPY ON Ca- 1 SIGNAL RESPONSE TO TREATMENT WITHIN WEEKS OF THERAPY IN ALL SUBJECTS evaluation by population based pharmacokinetic modelling techniques

EFFECT OF CALCIUM SUPPLEMENTATION 1 Ca/ 0 Ca isotope ratio in urine.e-10 3.E-10 2.E-10 1.E-10 ID 7 ID 8 ID 9 ID 10-100 0 100 200-100 0 100 200-100 0 100 200-100 0 100 200 5.E-10.E-10 Pla Ca 3.E-10 2.E-10 1.E-10 ID 16-100 0 100 200 7.E-10 5.E-10 Pla Pla Ca Ca 3.E-10 1.E-10 ID 17-100 0 100 200 ID 13-100 0 100 200 ID 12 Ca Ca Ca Pla Pla Pla -100 0 100 200 ID 11 Ca Ca Pla Pla -100 0 100 200 ID 1 Ca Pla -100 0 100 200 ID 20 Ca Ca Pla Pla -100 0 100 200 ID 15 Ca Pla -100 0 100 200 7.E-10 5.E-10 Pla Ca Pla Ca Pla Ca Pla Ca 3.E-10 1.E-10 ID 18-100 0 100 200 ID 19-100 0 100 200 ID 21-100 0 100 200 ID 22-100 0 100 200 Intervention period [days] 3 month blinded randomized placebo controlled supplementation trial 750 mg/d + 00 IU Vit D; 16 postmenopausal women

EFFECT OF CALCIUM SUPPLEMENTATION 1 Ca -55% p<0.001 Plasma P S B 35 mg Alendronate weekly Urine Bone Surface Deep Bone 1 Ca +27% p<0.001 +0% p<0.001 P S B 750 mg Ca daily Effect of intervention resolvable in each individual DIFFERENCES IN MECHANISMS OF ACTION CAN BE IDENTIFIED

FOCAL POINTS SINGAPORE GENETIC POLYMORPHISMS ACID BASE BALANCE ETHNIC DIFFERENCES PHYTOESTROGEN ES AND SOY OSTEOPOROSIS CALCIUM INTAKE PHYSICAL ACTIVITY TRACE ELEMENT NUTRITION VITAMIN D STATUS

THANK YOU FOR YOUR ATTENTION